MCM
OVID icon

Monimus Capital Management’s Ovid Therapeutics OVID Stock Holding History

Monimus Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-138,266
Closed -$129K – 60
2024
Q4 		$129K Buy
+138,266
New +$155K 0.12% 51

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Monimus Capital Management's OVID Position: Q1 2025 in Review

Monimus Capital Management sold out of Ovid Therapeutics (OVID) in Q1 2025, closing a stake of 138,266 shares — an estimated $129K sold.

Monimus Capital Management first reported a position in OVID in Q4 2024 and held it in 1 quarter. The position peaked at $129K in Q4 2024. 82 funds tracked by Wall St. Rank hold OVID as of Q1 2025.

  • Monimus Capital Management reported no remaining Ovid Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Monimus Capital Management sold 138,266 Ovid Therapeutics shares in Q1 2025, an estimated $129K.
  • Monimus Capital Management first reported a position in Ovid Therapeutics in Q4 2024 and held it in 1 quarter.
  • Monimus Capital Management's Ovid Therapeutics position peaked at $129K in Q4 2024.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2025.

Based on Monimus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.